Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.

Cancer science - 1 Aug 2007

Pan Jingxuan, Quintás-Cardama Alfonso, Manshouri Taghi, Cortes Jorge, Kantarjian Hagop, Verstovsek Srdan

Abstract excerpt

The activity of the novel tyrosine kinase inhibitor INNO-406 against human cells with mutated KIT was investigated. Human mast cell (HMC)-1.1 cells with juxtamembrane domain mutation V560G, and HMC-1.2 cells with both V560G and the kinase domain mutation D816V, were treated with INNO-406 (0.02-5....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate
Share to Mast Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Protein Isoforms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 17517053
DOI: 10.1111/j.1349-7006.2007.00516.x
PMCID: PMC11159391

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17517053-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.PMID 17517053Read ↗

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.Semantic proximity Read ↗

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.Semantic proximity Read ↗

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.Semantic proximity Read ↗

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.Semantic proximity Read ↗

Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.Semantic proximity Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.Semantic proximity Read ↗

C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.Semantic proximity Read ↗

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.Semantic proximity Read ↗

Capitalizing on paradoxical activation of the mitogen-activated protein kinase pathway for treatment of Imatinib-resistant mast cell leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.